Interventions for HIV-associated nephropathy.

ABSTRACT:

Background

Human immunodeficiency virus-associated nephropathy (HIVAN) is the most common cause of end stage kidney disease (ESKD) in human immunodeficiency virus-1 (HIV-1) serotype patients and it mostly affects patients of African descent. It rapidly progresses to ESKD if untreated. The goal of treatment is directed toward reducing HIV-1 replication and/or slowing the progression of chronic kidney disease. The following pharmacological agents have been used for the treatment of HIVAN: antiretroviral therapy, angiotensin-converting enzyme inhibitors (ACEi), steroids and recently cyclosporin. Despite this, the effect of each intervention is yet to be evaluated.

Objectives

To evaluate the benefits and harms of adjunctive therapies in the management of HIVAN and its effects on

SUBMITTER: Yahaya I 

PROVIDER: S-EPMC7209266 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature